Cargando…

Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial

BACKGROUND: Globally, hepatocellular carcinoma is the second most common cause of cancer deaths. It remains challenging to intensify cancer treatment without impairing liver function. OBJECTIVE: The objective of the TheraSphere in the Treatment of Patients with Unresectable Hepatocellular Carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chauhan, Nikhil, Bukovcan, Janet, Boucher, Eveline, Cosgrove, David, Edeline, Julien, Hamilton, Bonnie, Kulik, Laura, Master, Fayaz, Salem, Riad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JMIR Publications 2018
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115595/ https://www.ncbi.nlm.nih.gov/pubmed/30111528 http://dx.doi.org/10.2196/11234

Ejemplares similares

TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial
por: Chauhan, Nikhil, et al.
Publicado: (2019)

Radioembolization for Hepatocellular Carcinoma using TheraSphere(®)
por: Ali, Safiyya Mohamed
Publicado: (2011)

Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
por: Salem, Riad, et al.
Publicado: (2021)

Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma
por: Rognoni, Carla, et al.
Publicado: (2022)

ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs)
por: Sharma, Rohini, et al.
Publicado: (2022)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
por: Mahvash, Armeen, et al.
Publicado: (2016)

A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma
por: Zhen, Yanhua, et al.
Publicado: (2019)

Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma
por: Bi, Yonghua, et al.
Publicado: (2022)

Lobar Hepatocellular Carcinoma with Ipsilateral Portal Vein Tumor Thrombosis Treated with Yttrium-90 Glass Microsphere Radioembolization: Preliminary Results
por: Pracht, M., et al.
Publicado: (2013)

Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC
por: Veenstra, Emile B., et al.
Publicado: (2022)

Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors
por: Kucuk, Ozlem N, et al.
Publicado: (2011)

Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors
por: Kucuk, N Ozlem, et al.
Publicado: (2011)

Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma
por: Zhou, Tan-Yang, et al.
Publicado: (2020)

Assessment of radiation sensitivity of unresectable intrahepatic cholangiocarcinoma in a series of patients submitted to radioembolization with yttrium-90 resin microspheres
por: Depalo, Tommaso, et al.
Publicado: (2021)

Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib
por: Teyateeti, Ajalaya, et al.
Publicado: (2021)

Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer
por: Cohen, S J, et al.
Publicado: (2014)

Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma
por: Gabrielson, Andrew, et al.
Publicado: (2015)

Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma—An Evaluation of Predictors
por: Paprottka, Karolin J., et al.
Publicado: (2021)

Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases
por: Cosimelli, M, et al.
Publicado: (2010)

Yttrium-90 microsphere induced gastrointestinal tract ulceration
por: South, Christopher D, et al.
Publicado: (2008)

Trans-arterial hepatic radioembolisation of yttrium-90 microspheres
por: Murthy, R, et al.
Publicado: (2006)

Internal dosimetry for radioembolization therapy with Yttrium‐90 microspheres
por: Fallahpoor, Maryam, et al.
Publicado: (2017)

Utility of Quantitative (99m)Tc-MAA SPECT/CT for (90)yttrium-Labelled Microsphere Treatment Planning: Calculating Vascularized Hepatic Volume and Dosimetric Approach
por: Garin, Etienne, et al.
Publicado: (2011)

Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
por: Nabrinsky, Edward, et al.
Publicado: (2020)

Drug‐eluting bead transarterial chemoembolization with medium‐sized versus small‐sized CalliSpheres microspheres in unresectable primary liver cancer
por: Zhang, Jiao, et al.
Publicado: (2021)

Yttrium-90 Microsphere Radioembolization for Treatment of Lung Cancer Hepatic Metastases
por: Gaba, Ron C., et al.
Publicado: (2012)

Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate Cancer
por: Bunck, Alexander C., et al.
Publicado: (2017)

Standardizing SPECT/CT dosimetry following radioembolization with yttrium-90 microspheres
por: Kim, S. Peter, et al.
Publicado: (2021)

Yttrium-90 radioembolization of unresectable hepatocellular carcinoma – a single center experience
por: Meyer, Carsten, et al.
Publicado: (2017)

Side Effects of Yttrium-90 Radioembolization
por: Riaz, Ahsun, et al.
Publicado: (2014)

Normalization of drug and therapeutic concepts with Thera-Py
por: Cannon, Matthew, et al.
Publicado: (2023)

Advances in SPECT for Optimizing the Liver Tumors Radioembolization Using Yttrium-90 Microspheres
por: Roshan, Hoda Rezaei, et al.
Publicado: (2015)

The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres
por: Westcott, Mark A., et al.
Publicado: (2016)

Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review
por: Feretis, Michael, et al.
Publicado: (2020)

Hierarchically electrospraying a PLGA@chitosan sphere-in-sphere composite microsphere for multi-drug-controlled release
por: Liu, Zhu, et al.
Publicado: (2020)

Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial
por: Chan, Stephen Lam, et al.
Publicado: (2022)

Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres
por: Ebbers, S. C., et al.
Publicado: (2020)

Transradial versus transfemoral arterial access in Yttrium-90 microspheres radioembolization for hepatocellular carcinoma
por: Ghosh, Abheek, et al.
Publicado: (2022)

Thera-SAbDab: the Therapeutic Structural Antibody Database
por: Raybould, Matthew I J, et al.
Publicado: (2020)

International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres
por: Levillain, Hugo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mnmptb135r8213u1cn148apfpd